Seroma of the Mammary Gland

Launched by UNIVERSITY HOSPITAL AUGSBURG · Jun 1, 2023

Keywords

ClinConnect Summary

This clinical trial, called "Seroma of the Mammary Gland," is investigating a condition known as seroma, which can occur after surgeries like mastectomy in patients with breast cancer. A seroma is a buildup of fluid in the area where tissue has been removed, and it can cause complications, especially for those who receive breast implants. The study aims to gather information about postoperative seromas to improve patient care and outcomes.

Women aged 18 and older who are undergoing surgery for breast cancer, including procedures that involve removing breast tissue and placing implants or expanders, may be eligible to participate. Participants will be asked to provide informed consent, meaning they agree to take part in the study after understanding what it involves. Throughout the trial, participants can expect to be closely monitored for any complications, including seromas, and their experiences will contribute to a larger database designed to help improve future treatments.

Gender

FEMALE

Eligibility criteria

• Inclusion criteria study group and control group 1:
• • Written informed consent
• • Age ≥ 18 years
• • all stages of DCIS or primary breast cancer (T1-T4, N0 or N+, M0) including all histopathological subtypes (ER/PR positive, ER positive/PR negative, Her-2/neu positive and triple negative)
• • Surgical procedure planned including ablatio or subcutaneous mastectomy with implant or expander insertion
• Inclusion criteria control group 2 and 3:
• • Written informed consent
• • Age ≥ 18 years
• • Surgical procedure planned with implant or expander insertion with or without subcutaneous mastectomy
• Exclusion criteria:
• • Age \<18 years
• • Male sex
• • Breast cancer patients planned for breast conserving therapy
• • Recurrent breast cancer disease
• • History of breast surgery
• • Diagnosis of LCIS only
• • Pregnancy at time of diagnosis
• • Patients with a known immunodeficiency